MX2011012183A - Composicion farmaceutica para el tratamiento de enfermedades cardiacas. - Google Patents

Composicion farmaceutica para el tratamiento de enfermedades cardiacas.

Info

Publication number
MX2011012183A
MX2011012183A MX2011012183A MX2011012183A MX2011012183A MX 2011012183 A MX2011012183 A MX 2011012183A MX 2011012183 A MX2011012183 A MX 2011012183A MX 2011012183 A MX2011012183 A MX 2011012183A MX 2011012183 A MX2011012183 A MX 2011012183A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
treatment
heart diseases
composition
parmaceutical composition
Prior art date
Application number
MX2011012183A
Other languages
English (en)
Inventor
Christian Homsy
Roland Gordon-Beresford
Vinciane Gaussin
Original Assignee
Cardio3 Biosciences Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardio3 Biosciences Sa filed Critical Cardio3 Biosciences Sa
Publication of MX2011012183A publication Critical patent/MX2011012183A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1406—Septums, pierceable membranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1412—Containers with closing means, e.g. caps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1468—Containers characterised by specific material properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende células dedicadas a la generación de tejido cardiaco y por lo menos un excipiente farmacéuticamente aceptable producido de acuerdo con estándares reconocidos internacionalmente para la manufactura de productos farmacéuticos, un proceso para la manufactura de esta composición farmacéutica y un kit para la administración de la composición farmacéutica el cual comprende un envase que contiene la composición farmacéutica.
MX2011012183A 2009-05-20 2010-05-20 Composicion farmaceutica para el tratamiento de enfermedades cardiacas. MX2011012183A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2009056197 2009-05-20
PCT/EP2010/057004 WO2010133686A1 (en) 2009-05-20 2010-05-20 Parmaceutical composition for the treatment of heart diseases.

Publications (1)

Publication Number Publication Date
MX2011012183A true MX2011012183A (es) 2012-03-06

Family

ID=41323568

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012183A MX2011012183A (es) 2009-05-20 2010-05-20 Composicion farmaceutica para el tratamiento de enfermedades cardiacas.

Country Status (16)

Country Link
US (2) US9446076B2 (es)
JP (1) JP6029468B2 (es)
KR (1) KR101689415B1 (es)
CN (2) CN107028980A (es)
AU (1) AU2010251151B2 (es)
BR (1) BRPI1012116A2 (es)
CA (1) CA2762584A1 (es)
ES (1) ES2541212T3 (es)
HK (1) HK1163500A1 (es)
IL (1) IL216399A0 (es)
MX (1) MX2011012183A (es)
NZ (2) NZ623454A (es)
RU (1) RU2595801C2 (es)
SG (1) SG175880A1 (es)
TW (1) TWI492707B (es)
WO (1) WO2010133686A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2269461B1 (en) 2004-07-30 2017-03-22 Mayo Foundation For Medical Education And Research Treating cardiovascular tissue
US9765298B2 (en) 2006-07-24 2017-09-19 Mayo Foundation For Medical Education And Research Methods and materials for providing cardiac cells
WO2009145761A1 (en) 2008-05-27 2009-12-03 Mayo Foundation For Medical Education And Research Methods and materials for using cells to treat heart tissue
WO2011057249A2 (en) * 2009-11-09 2011-05-12 The Brigham And Women's Hospital, Inc. Treatment of heart disease
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
WO2013007284A1 (en) * 2011-07-08 2013-01-17 Mikael Sigvardsson A method for enriching mesenchymal stem cells and applications thereof
US20150104428A1 (en) * 2012-03-30 2015-04-16 University Of Southern California Compositions and Treatment Methods for Mesenchymal Stem Cell-Induced Immunoregulation
WO2013163479A1 (en) * 2012-04-25 2013-10-31 General Istrazivanja D.O.O. Methods and compositions for treating and diagnosing acute myocardial infarction
US9943545B2 (en) * 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
SG11201510045TA (en) * 2013-06-28 2016-01-28 Otsuka Pharma Co Ltd Trehalose and dextran-containing solution for transplanting mammalian cells
CN103667440A (zh) * 2013-09-05 2014-03-26 谢小冬 Gata4基因snp位点的用途
CN104922155A (zh) * 2014-03-18 2015-09-23 中山大学孙逸仙纪念医院 治疗心脏疾病的细胞输送方法
EP3712254A1 (en) 2014-05-28 2020-09-23 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
US10363278B2 (en) 2014-06-15 2019-07-30 Amnio Technology Llc Frozen therapeutic dose and package
US11584916B2 (en) 2014-10-17 2023-02-21 Children's Hospital Medical Center Method of making in vivo human small intestine organoids from pluripotent stem cells
IL305070A (en) 2014-12-30 2023-10-01 Cell Cure Neurosciences Ltd RPE cell populations and methods for their production
AU2016226087A1 (en) 2015-03-03 2017-10-26 Regents Of The University Of Minnesota ETV2 and uses thereof
CN108472318A (zh) * 2015-06-30 2018-08-31 明尼苏达大学校董会 人源化心脏肌肉
CN105079791A (zh) * 2015-09-18 2015-11-25 郑榆坤 一种刺激体内内源干细胞的组合物及其应用
WO2017064688A1 (en) * 2015-10-15 2017-04-20 Cells For Cells, S.P.A. Neurite regeneration therapy based on exosomes derived from menstrual stem cells
US11534466B2 (en) 2016-03-09 2022-12-27 Aal Scientifics, Inc. Pancreatic stem cells and uses thereof
EP4177335A1 (en) 2016-05-05 2023-05-10 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
CN106619718A (zh) * 2016-10-18 2017-05-10 广州赛莱拉干细胞科技股份有限公司 一种细胞制剂及其制备方法和应用
CN106474456A (zh) * 2016-10-18 2017-03-08 广州赛莱拉干细胞科技股份有限公司 一种细胞制剂及其制备方法和应用
CN108070645A (zh) * 2016-11-11 2018-05-25 中国科学院上海生命科学研究院 Stx-t在预防和/或治疗贫血或其相关疾病的应用
SG10202105768WA (en) 2016-12-05 2021-06-29 Childrens Hospital Med Ct Colonic organoids and methods of making and using same
DE102017116204B4 (de) * 2017-07-18 2024-06-27 Universität Rostock Verfahren zur Vorhersage der Antwort auf die kardiovaskuläre Regeneration
CN109497038A (zh) * 2017-09-14 2019-03-22 青岛瑞思德生物科技有限公司 一种脂肪保存液及其制备方法
CN107648592B (zh) * 2017-11-13 2021-05-14 深圳市喆邦生物工程有限公司 趋化因子ccl4作为制备治疗骨折药物的应用
WO2019130061A2 (en) * 2017-12-29 2019-07-04 Cell Cure Neurosciences Ltd. Retinal pigment epithelium cell compositions
CN108244096B (zh) * 2018-01-10 2019-01-04 暨赛再生医学科技有限公司 一种长期保存过表达vegf的血管内皮祖细胞的保存液
CN108379662A (zh) * 2018-02-08 2018-08-10 深圳大图科创技术开发有限公司 一种干细胞在心脏移植模型的应用
CN108546757B (zh) * 2018-03-05 2021-09-07 上海长海医院 Zfpm2-as1在制备胃癌诊断试剂或试剂盒中的应用
CN110812369A (zh) * 2018-08-10 2020-02-21 浙江楚沅生物科技有限公司 用于治疗组织坏死或改善心脏功能的药物
CN109266604B (zh) * 2018-10-10 2020-11-10 浙江神雁精准医疗科技有限公司 包含干细胞活性物质的组合物及其制备方法
CN109769799A (zh) * 2019-03-20 2019-05-21 江苏瑞思坦生物科技有限公司 一种人脂肪组织保存液及其制备方法
CN111939245B (zh) * 2019-05-16 2024-03-01 龚笑海 一种心脏治疗和保护的药物组合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6045990A (en) * 1998-07-09 2000-04-04 Baust; John M. Inclusion of apoptotic regulators in solutions for cell storage at low temperature
US6632666B2 (en) * 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
US20040071665A1 (en) 2000-09-05 2004-04-15 Yong-Fu Xiao Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal
US6921633B2 (en) * 2002-11-18 2005-07-26 Biolife Solutions Incorporated Methods and compositions for the preservation of cells, tissues or organs in the vitreous state
KR100674783B1 (ko) * 2003-12-09 2007-01-25 (주)안트로젠 세포 이식을 위한 세포의 생산 방법
EP2269461B1 (en) 2004-07-30 2017-03-22 Mayo Foundation For Medical Education And Research Treating cardiovascular tissue
WO2006080434A1 (ja) 2005-01-27 2006-08-03 Japan Health Sciences Foundation 間葉系幹細胞を含む細胞シート
AU2006244639A1 (en) * 2005-03-31 2006-11-16 Mytogen, Inc. Treatment for heart disease
US8074465B2 (en) * 2005-09-12 2011-12-13 Genzyme Corporation Thermally insulated transport container for cell-based products and related methods
US9765298B2 (en) * 2006-07-24 2017-09-19 Mayo Foundation For Medical Education And Research Methods and materials for providing cardiac cells
US20100203021A1 (en) 2007-01-09 2010-08-12 Lead Pharma Cel Models Ip B.V. Provision of new cardiomyocyte progenitor cells and cardiomyocytes derived therefrom
US20100189697A1 (en) * 2007-03-07 2010-07-29 Andre Terzic Cardiac-specific progenitor cells
KR20080103637A (ko) * 2007-05-25 2008-11-28 주식회사 알앤엘바이오 지방유래 줄기세포를 함유하는 사지말단부 허혈성 질환의세포치료용 조성물
FR2917381B1 (fr) 2007-06-15 2009-10-16 Ceva Sante Animale Sa Conditionnement plastique multicouche pour la conservation d'une composition pharmaceutique
JP5542686B2 (ja) * 2007-12-04 2014-07-09 プロテオバイオアクティブズ・ピーティーワイ・リミテッド 前駆細胞の保護およびその分化の調節
EP2100954A1 (en) * 2008-03-10 2009-09-16 Assistance Publique - Hopitaux de Paris Method for generating primate cardiac progenitor cells for clinical use from primate embryonic stem cells, and their applications
EP2271208A1 (en) * 2008-03-27 2011-01-12 Biolife Solutions, Inc. Mehtod, system, and apparatus for hypothermic collection, storage, transport and banking of birth tissue
WO2009145761A1 (en) 2008-05-27 2009-12-03 Mayo Foundation For Medical Education And Research Methods and materials for using cells to treat heart tissue
BE1018733A3 (fr) 2009-04-29 2011-07-05 Cardio3 Biosciences Sa Dispositif pour la delivrance d'un agent therapeutique.

Also Published As

Publication number Publication date
US10086016B2 (en) 2018-10-02
CN102438636A (zh) 2012-05-02
RU2011145370A (ru) 2013-06-27
KR20120046107A (ko) 2012-05-09
IL216399A0 (en) 2012-01-31
WO2010133686A8 (en) 2012-03-08
US9446076B2 (en) 2016-09-20
AU2010251151B2 (en) 2015-08-20
US20160279168A1 (en) 2016-09-29
JP2012527432A (ja) 2012-11-08
TWI492707B (zh) 2015-07-21
AU2010251151A1 (en) 2011-11-24
CA2762584A1 (en) 2010-11-25
NZ623454A (en) 2015-12-24
US20120128638A1 (en) 2012-05-24
ES2541212T3 (es) 2015-07-16
BRPI1012116A2 (pt) 2016-03-15
SG175880A1 (en) 2011-12-29
CN107028980A (zh) 2017-08-11
RU2595801C2 (ru) 2016-08-27
JP6029468B2 (ja) 2016-11-24
HK1163500A1 (en) 2012-09-14
WO2010133686A1 (en) 2010-11-25
KR101689415B1 (ko) 2016-12-23
NZ596162A (en) 2014-06-27
TW201108935A (en) 2011-03-16

Similar Documents

Publication Publication Date Title
MX2011012183A (es) Composicion farmaceutica para el tratamiento de enfermedades cardiacas.
MX2012000565A (es) Derivados de triterpeno tipo lupeol como antivirales.
PH12016500040A1 (en) Pcsk9 vaccine
MX2012012952A (es) Compuestos de 2, 5, 6, 7,-tetrahidro-[1, 4] oxazepin-3-ilamina o 2, 3, 6, 7-tetrahidro-[1, 4] oxazepin-5-ilamina.
MX337830B (es) Peptidos utiles en el tratamiento y/o cuidado de la piel y/o cabello y su uso en composiciones cosmeticas o farmaceuticas.
MX2013002453A (es) Analogos deuterados de pridopidina utiles como estabilizadores dopaminergicos.
TN2011000370A1 (en) Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof
MD20140059A2 (en) Substituted 4-phenyl-pyridines for the treatment of NK-1 receptor related diseases
TN2012000143A1 (en) Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
EA201270492A1 (ru) Соединения для лечения дислипидемии и связанных с ней заболеваний
EP2415749A4 (en) NEW SALVIANOLIC ACID CONNECTION L, PREPARATION METHOD AND USE
MY156302A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
MX2013008478A (es) 1, 4 riazepinas/sulfonas como inhibidores de beta secretasa 1 (base1) y/o beta secretasa 2 (bace2).
MY169485A (en) Heterocyclic compounds suitable for the treatment of dyslipidemia
NZ700824A (en) Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
TN2011000595A1 (en) Substituted piperidines
MX2012000954A (es) Composicion far,aceutica topica que incuye la rel-n-[6-[(2r,6s)-2,6-dimetil-4-morfolinil]-3-piridinil]-2-metil- 4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida.
ATE526015T1 (de) Arzneimittel sowie deren herstellung und verwendung bei der behandlung von schmerzhaften neuropathien
PH12014501943A1 (en) Novel compounds for the treatment of dyslipidemia and related diseases
MX2013003523A (es) Composicion farmaceutica de dosis baja.
TN2011000596A1 (en) Substituted piperidines
GEP201706607B (en) Method for producing and using copolymer of sodium carboxymethyl cellulose and gossypol
EP2476422A4 (en) PHARMACEUTICAL COMPOSITION FOR ANTI-THROMBOTIC DISEASES, METHOD FOR PREPARING SAME AND USE THEREOF
MX2010008433A (es) Uso de ranolazina para el tratamiento de enfermedades cardiovasculares.

Legal Events

Date Code Title Description
FG Grant or registration